PEN
Penumbra, Inc.
Price Chart
Latest Quote
$316.20
-1.00 (-0.32%)
Current Price
| Previous Close | $317.20 |
| Open | $316.27 |
| Day High | $316.91 |
| Day Low | $315.03 |
| Volume | 173,198 |
Stock Information
| Shares Outstanding | 39.33M |
| Total Debt | $216.18M |
| Cash Equivalents | $615.66M |
| Revenue | $1.45B |
| Net Income | $171.05M |
| Sector | Healthcare |
| Industry | Medical Devices |
| Market Cap | $12.44B |
| P/E Ratio | 72.69 |
| EPS (TTM) | $4.35 |
| Exchange | NYQ |
đ Comprehensive Analysis
Company Data
| Enterprise Value | $12.08B |
| Sales | $1.45B |
| Income | $171.05M |
| Book/sh | $37.48 |
| Cash/sh | $15.65 |
| Employees | 5K |
Financial Ratios
| Quick Ratio | 3.77 |
| Current Ratio | 6.02 |
| Debt/Eq | 14.67 |
| EPS Growth TTM | -16.90% |
Returns & Margins
| ROA | 6.70% |
| ROE | 12.73% |
| Gross Margin | 67.38% |
| Operating Margin | 10.20% |
| Profit Margin | 11.76% |
Ownership
| Insider Ownership | 2.90% |
| Institutional Ownership | 88.97% |
| Insider & Institutional transactions data not available | |
Valuation Ratios
| Forward P/E | 50.33 |
| PEG | 0.73 |
| P/S | 8.55 |
| P/B | 8.44 |
Analyst Data
| Recommendation | hold |
| Target Price | $363.36 |
Technical Indicators
| SMA20 | $319.82 |
| SMA50 | $324.17 |
| SMA200 | $307.70 |
| RSI | 38.42 |
| ATR | 2.2764 |
| Shares Float | 38.23M |
| Short Float | 5.60% |
| Short Ratio | 4.36 |
| Volatility | 0.70 |
| Rel Volume | 0.41 |
Performance History
| Week | -0.79% |
| Month | -3.41% |
| Quarter | -5.85% |
| 6 Months | +2.24% |
| YTD | +2.19% |
| Year | +23.03% |
| 3 Years | -6.32% |
| 5 Years | +13.98% |
| 10 Years | +427.00% |
Stock Score:
â Premium
Based on debt, profitability, growth, and cash flow metrics
â Premium Feature
Sign up for free to view detailed scoring breakdown â premium is free during our trial period!
Recent Price History
| Date | Close | Volume |
|---|---|---|
| 2026-06-22 | $316.20 | 173,198 |
| 2026-06-18 | $317.20 | 679,700 |
| 2026-06-17 | $316.16 | 384,700 |
| 2026-06-16 | $318.46 | 279,300 |
| 2026-06-15 | $318.21 | 446,300 |
| 2026-06-12 | $318.71 | 514,500 |
| 2026-06-11 | $318.32 | 335,800 |
| 2026-06-10 | $319.34 | 460,400 |
| 2026-06-09 | $321.06 | 441,300 |
| 2026-06-08 | $320.07 | 279,300 |
| 2026-06-05 | $320.53 | 278,800 |
| 2026-06-04 | $320.63 | 823,400 |
| 2026-06-03 | $319.37 | 402,700 |
| 2026-06-02 | $318.74 | 397,300 |
| 2026-06-01 | $318.95 | 362,700 |
| 2026-05-29 | $318.30 | 337,800 |
| 2026-05-28 | $318.95 | 470,800 |
| 2026-05-27 | $320.34 | 532,600 |
| 2026-05-26 | $328.20 | 321,800 |
About Penumbra, Inc.
Penumbra, Inc., together with its subsidiaries, designs, develops, manufactures, and markets medical devices in the United States and internationally. It offers computer-assisted vacuum thrombectomy; peripheral thrombectomy products, including the Indigo System for power aspiration of thrombus in the body; Lightning Flash, a mechanical thrombectomy system; Lightning Bolt 7, an arterial thrombectomy system; and CAT RX. It also provides access products, including guide catheters and the Penumbra distal delivery catheters under the Neuron, Neuron MAX, BENCHMARK, BMX, DDC, Access25; MIDWAY, and PX SLIM brands; Penumbra System, an integrated mechanical thrombectomy system comprising reperfusion catheters and separators, the 3D Revascularization device, aspiration tubing, aspiration pump, and other components and accessories under the Penumbra RED, SENDit, JET, ACE, BMX, Max, 3D Revascularization Device, and Penumbra ENGINE brands; and neuro embolization coiling systems that include the Penumbra Coil 400, for the treatment of aneurysms and other complex lesions, detachable coils of neurovascular lesions under the Penumbra SMART COIL, SwiftSET, and Penumbra SwiftPAC Coil brands; and POD400 and PAC400 brands. In addition, it provides peripheral embolization products, such as Ruby Embolization Platform, which consists of detachable coils for peripheral applications; Ruby LP and XL Embolization Platform; Penumbra LANTERN Delivery Microcatheter, a low-profile microcatheter with a high-flow lumen; POD (Penumbra Occlusion Device) System, a single device solution; Packing Coil LP; and Packing Coil, a complementary device for use in other peripheral embolization products. Further, it offers neurosurgical tools comprising the Artemis Neuro Evacuation Device for surgical removal of fluid and tissue from the ventricles and cerebrum. It sells its products through direct sales organizations and distributors. The company was incorporated in 2004 and is based in Alameda, California.
đ° Latest News
GMED vs. PEN: Which Stock Should Value Investors Buy Now?
Zacks âĸ 2026-06-22T15:40:02Z
Penumbra Receives CE Nod for THUNDERBOLT: Stock to Gain?
Zacks âĸ 2026-06-18T16:47:00Z
ClearPoint Neuro (CLPT) Surges 26.0%: Is This an Indication of Further Gains?
Zacks âĸ 2026-06-18T10:36:00Z
Penumbra wins CE mark for Thunderbolt clot removal tech
MedTech Dive âĸ 2026-06-18T10:00:00Z
Medtech M&A maintains momentum following decade-high 2025: PwC
MedTech Dive âĸ 2026-06-17T11:00:00Z
Penumbraâs Thunderbolt approval poised to accelerate neuro thrombectomy innovation
Medical Device Network âĸ 2026-06-16T16:27:49Z
Boston Scientific Eyes Neurovascular Growth With Penumbra Thunderbolt Clearance
Simply Wall St. âĸ 2026-06-13T07:17:08Z
FDA clears Penumbraâs Thunderbolt thrombectomy platform for stroke
Medical Device Network âĸ 2026-06-12T15:34:29Z
Penumbra's Thunderbolt Device Offers Revenue Upside Not Reflected in Estimates, RBC Says
MT Newswires âĸ 2026-06-12T14:52:32ZPenumbraâs FDA nod for clot removal tech a win for Boston Scientific
MedTech Dive âĸ 2026-06-12T11:22:35Z
Period:
Loading...
Income Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Revenue | ||||
| Reconciled Cost Of Revenue | $461,228,000 | $439,620,000 | $375,879,000 | $311,926,000 |
| Cost Of Revenue | $461,228,000 | $439,620,000 | $375,879,000 | $311,926,000 |
| Total Revenue | $1,403,665,000 | $1,194,615,000 | $1,058,522,000 | $847,133,000 |
| Operating Revenue | $1,403,665,000 | $1,194,615,000 | $1,058,522,000 | $847,133,000 |
| Expenses | ||||
| Interest Expense | $1,311,000 | $1,418,000 | $1,739,000 | $1,749,000 |
| Total Expenses | $1,214,416,000 | $1,108,391,000 | $966,756,000 | $841,051,000 |
| Other Income Expense | $893,000 | $-77,627,000 | $-17,202,000 | $-2,327,000 |
| Other Non Operating Income Expenses | $893,000 | $-682,000 | $1,013,000 | $-2,327,000 |
| Net Non Operating Interest Income Expense | $14,983,000 | $12,272,000 | $5,086,000 | $137,000 |
| Interest Expense Non Operating | $1,311,000 | $1,418,000 | $1,739,000 | $1,749,000 |
| Operating Expense | $753,188,000 | $668,771,000 | $590,877,000 | $529,125,000 |
| Income & Earnings | ||||
| Net Income From Continuing Operation Net Minority Interest | $177,687,000 | $14,012,000 | $90,954,000 | $-2,002,000 |
| Net Interest Income | $14,983,000 | $12,272,000 | $5,086,000 | $137,000 |
| Interest Income | $16,294,000 | $13,690,000 | $6,825,000 | $1,886,000 |
| Normalized Income | $177,687,000 | $65,642,095 | $105,343,850 | $-2,002,000 |
| Net Income From Continuing And Discontinued Operation | $177,687,000 | $14,012,000 | $90,954,000 | $-2,002,000 |
| Total Operating Income As Reported | $189,249,000 | $9,279,000 | $73,551,000 | $6,082,000 |
| Net Income Common Stockholders | $177,687,000 | $14,012,000 | $90,954,000 | $-2,002,000 |
| Net Income | $177,687,000 | $14,012,000 | $90,954,000 | $-2,002,000 |
| Net Income Including Noncontrolling Interests | $177,687,000 | $14,012,000 | $90,954,000 | $-2,002,000 |
| Net Income Continuous Operations | $177,687,000 | $14,012,000 | $90,954,000 | $-2,002,000 |
| Pretax Income | $205,125,000 | $20,869,000 | $79,650,000 | $3,892,000 |
| Special Income Charges | $0 | $-76,945,000 | $-18,215,000 | $0 |
| Interest Income Non Operating | $16,294,000 | $13,690,000 | $6,825,000 | $1,886,000 |
| Operating Income | $189,249,000 | $86,224,000 | $91,766,000 | $6,082,000 |
| Gross Profit | $942,437,000 | $754,995,000 | $682,643,000 | $535,207,000 |
| Per Share | ||||
| Diluted EPS | $4.52 | $0.36 | $2.32 | $-0.05 |
| Basic EPS | $4.57 | $0.36 | $2.37 | $-0.05 |
| Other | ||||
| Tax Effect Of Unusual Items | $0 | $-25,314,905 | $-3,825,150 | $0 |
| Tax Rate For Calcs | $0 | $0 | $0 | $0 |
| Normalized EBITDA (Bullshit earnings) | $223,907,000 | $122,934,000 | $126,861,000 | $29,962,000 |
| Total Unusual Items | $0 | $-76,945,000 | $-18,215,000 | $0 |
| Total Unusual Items Excluding Goodwill | $0 | $-76,945,000 | $-18,215,000 | $0 |
| Reconciled Depreciation | $17,471,000 | $23,702,000 | $27,257,000 | $24,321,000 |
| EBITDA (Bullshit earnings) | $223,907,000 | $45,989,000 | $108,646,000 | $29,962,000 |
| EBIT | $206,436,000 | $22,287,000 | $81,389,000 | $5,641,000 |
| Diluted Average Shares | $39,291,828 | $39,268,037 | $39,216,564 | $37,841,874 |
| Basic Average Shares | $38,918,493 | $38,633,744 | $38,401,171 | $37,841,874 |
| Diluted NI Availto Com Stockholders | $177,687,000 | $14,012,000 | $90,954,000 | $-2,002,000 |
| Tax Provision | $27,438,000 | $6,857,000 | $-11,304,000 | $5,894,000 |
| Write Off | $0 | - | - | - |
| Research And Development | $89,766,000 | $94,783,000 | $84,423,000 | $79,407,000 |
| Selling General And Administration | $663,422,000 | $573,988,000 | $506,454,000 | $449,718,000 |
| Impairment Of Capital Assets | - | $76,945,000 | $0 | $0 |
| Minority Interests | - | - | $0 | $0 |
| Other Special Charges | - | - | $18,215,000 | - |
Fetched: 2026-06-21
Balance Sheet (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Assets | ||||
| Net Tangible Assets | $1,254,024,000 | $977,910,000 | $929,579,000 | $741,088,000 |
| Total Assets | $1,826,519,000 | $1,533,181,000 | $1,556,305,000 | $1,370,886,000 |
| Total Non Current Assets | $609,835,000 | $582,056,000 | $640,903,000 | $615,187,000 |
| Other Non Current Assets | $40,716,000 | $40,939,000 | $25,880,000 | $12,793,000 |
| Non Current Deferred Assets | $79,188,000 | $100,332,000 | $85,158,000 | $64,213,000 |
| Non Current Deferred Taxes Assets | $79,188,000 | $100,332,000 | $85,158,000 | $64,213,000 |
| Goodwill And Other Intangible Assets | $173,579,000 | $173,021,000 | $249,365,000 | $257,770,000 |
| Other Intangible Assets | $6,829,000 | $7,195,000 | $83,095,000 | $91,724,000 |
| Current Assets | $1,216,684,000 | $951,125,000 | $915,402,000 | $755,699,000 |
| Other Current Assets | $50,298,000 | $36,589,000 | $36,424,000 | $30,279,000 |
| Inventory | $431,549,000 | $406,737,000 | $388,023,000 | $334,006,000 |
| Receivables | $190,021,000 | $167,668,000 | $201,768,000 | $203,384,000 |
| Accounts Receivable | $190,021,000 | $167,668,000 | $201,768,000 | $203,384,000 |
| Allowance For Doubtful Accounts Receivable | $-2,350,000 | $-5,638,000 | $-3,169,000 | $-862,000 |
| Gross Accounts Receivable | $192,371,000 | $173,306,000 | $204,937,000 | $204,246,000 |
| Cash Cash Equivalents And Short Term Investments | $544,816,000 | $340,131,000 | $289,187,000 | $188,030,000 |
| Cash And Cash Equivalents | $186,897,000 | $324,404,000 | $167,486,000 | $69,858,000 |
| Prepaid Assets | - | - | - | - |
| Debt | ||||
| Total Debt | $219,699,000 | $223,389,000 | $234,343,000 | $235,773,000 |
| Long Term Debt And Capital Lease Obligation | $203,465,000 | $208,799,000 | $220,909,000 | $223,820,000 |
| Current Debt And Capital Lease Obligation | $16,234,000 | $14,590,000 | $13,434,000 | $11,953,000 |
| Liabilities | ||||
| Total Liabilities Net Minority Interest | $398,916,000 | $382,250,000 | $377,361,000 | $372,028,000 |
| Total Non Current Liabilities Net Minority Interest | $215,783,000 | $223,905,000 | $226,217,000 | $227,096,000 |
| Other Non Current Liabilities | $12,318,000 | $15,106,000 | $5,308,000 | $3,276,000 |
| Current Liabilities | $183,133,000 | $158,345,000 | $151,144,000 | $144,932,000 |
| Payables And Accrued Expenses | $166,899,000 | $143,755,000 | $130,725,000 | $123,821,000 |
| Payables | $34,736,000 | $31,326,000 | $27,155,000 | $26,679,000 |
| Accounts Payable | $34,736,000 | $31,326,000 | $27,155,000 | $26,679,000 |
| Current Deferred Liabilities | - | $940,000 | $6,985,000 | $9,158,000 |
| Equity | ||||
| Common Stock Equity | $1,427,603,000 | $1,150,931,000 | $1,178,944,000 | $998,858,000 |
| Total Equity Gross Minority Interest | $1,427,603,000 | $1,150,931,000 | $1,178,944,000 | $998,858,000 |
| Stockholders Equity | $1,427,603,000 | $1,150,931,000 | $1,178,944,000 | $998,858,000 |
| Gains Losses Not Affecting Retained Earnings | $4,348,000 | $-5,843,000 | $-3,151,000 | $-8,124,000 |
| Other Equity Adjustments | $4,348,000 | $-5,843,000 | $-3,151,000 | $-8,124,000 |
| Retained Earnings | $237,691,000 | $60,004,000 | $134,858,000 | $43,904,000 |
| Other | ||||
| Ordinary Shares Number | $39,229,670 | $38,490,836 | $38,681,549 | $38,107,977 |
| Share Issued | $39,229,670 | $38,490,836 | $38,681,549 | $38,107,977 |
| Tangible Book Value | $1,254,024,000 | $977,910,000 | $929,579,000 | $741,088,000 |
| Invested Capital | $1,427,603,000 | $1,150,931,000 | $1,178,944,000 | $998,858,000 |
| Working Capital | $1,033,551,000 | $792,780,000 | $764,258,000 | $610,767,000 |
| Capital Lease Obligations | $219,699,000 | $223,389,000 | $234,343,000 | $235,773,000 |
| Total Capitalization | $1,427,603,000 | $1,150,931,000 | $1,178,944,000 | $998,858,000 |
| Additional Paid In Capital | $1,185,525,000 | $1,096,732,000 | $1,047,198,000 | $963,040,000 |
| Capital Stock | $39,000 | $38,000 | $39,000 | $38,000 |
| Common Stock | $39,000 | $38,000 | $39,000 | $38,000 |
| Preferred Stock | $0 | $0 | $0 | $0 |
| Long Term Capital Lease Obligation | $203,465,000 | $208,799,000 | $220,909,000 | $223,820,000 |
| Current Capital Lease Obligation | $16,234,000 | $14,590,000 | $13,434,000 | $11,953,000 |
| Current Accrued Expenses | $132,163,000 | $112,429,000 | $103,570,000 | $97,142,000 |
| Goodwill | $166,750,000 | $165,826,000 | $166,270,000 | $166,046,000 |
| Net PPE | $316,352,000 | $267,764,000 | $280,500,000 | $280,411,000 |
| Accumulated Depreciation | $-71,356,000 | $-69,496,000 | $-51,752,000 | $-41,725,000 |
| Gross PPE | $387,708,000 | $337,260,000 | $332,252,000 | $322,136,000 |
| Leases | $37,397,000 | $36,687,000 | $29,241,000 | $25,611,000 |
| Construction In Progress | $57,693,000 | $3,781,000 | $3,535,000 | $7,523,000 |
| Other Properties | $199,559,000 | $205,805,000 | $219,848,000 | $225,959,000 |
| Machinery Furniture Equipment | $93,059,000 | $90,987,000 | $79,628,000 | $63,043,000 |
| Properties | $0 | $0 | $0 | $0 |
| Finished Goods | $268,173,000 | $237,057,000 | $234,023,000 | $216,427,000 |
| Work In Process | $46,275,000 | $35,713,000 | $34,489,000 | $26,793,000 |
| Raw Materials | $117,101,000 | $133,967,000 | $119,511,000 | $90,786,000 |
| Other Short Term Investments | $357,919,000 | $15,727,000 | $121,701,000 | $118,172,000 |
| Current Deferred Revenue | - | $940,000 | $6,985,000 | $9,158,000 |
| Treasury Shares Number | - | - | $0 | - |
| Minority Interest | - | - | - | - |
| Current Provisions | - | - | - | - |
Fetched: 2026-06-21
Cash Flow Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Free Cash Flow | ||||
| Free Cash Flow | $174,934,000 | $147,299,000 | $82,120,000 | $-74,959,000 |
| Operating Activities | ||||
| Operating Cash Flow | $238,663,000 | $168,481,000 | $97,333,000 | $-55,661,000 |
| Cash Flow From Continuing Operating Activities | $238,663,000 | $168,481,000 | $97,333,000 | $-55,661,000 |
| Investing Activities | ||||
| Capital Expenditure | $-63,729,000 | $-21,182,000 | $-15,213,000 | $-19,298,000 |
| Investing Cash Flow | $-404,590,000 | $77,624,000 | $-16,076,000 | $54,790,000 |
| Cash Flow From Continuing Investing Activities | $-404,590,000 | $77,624,000 | $-16,076,000 | $54,790,000 |
| Net Other Investing Changes | - | $1,100,000 | $-1,488,000 | - |
| Financing Activities | ||||
| Repurchase Of Capital Stock | $0 | $-100,387,000 | $0 | $0 |
| Financing Cash Flow | $26,532,000 | $-87,006,000 | $16,203,000 | $11,622,000 |
| Cash Flow From Continuing Financing Activities | $26,532,000 | $-87,006,000 | $16,203,000 | $11,622,000 |
| Net Other Financing Charges | $-2,802,000 | $-1,517,000 | $-2,229,000 | $-8,179,000 |
| Net Common Stock Issuance | $0 | $-100,387,000 | $0 | $0 |
| Issuance Of Capital Stock | - | - | - | $0 |
| Common Stock Issuance | - | - | - | $0 |
| Other | ||||
| Repayment Of Debt | $-2,485,000 | $-2,276,000 | $-1,981,000 | $-1,751,000 |
| End Cash Position | $186,897,000 | $324,404,000 | $167,486,000 | $69,858,000 |
| Beginning Cash Position | $324,404,000 | $167,486,000 | $69,858,000 | $59,379,000 |
| Effect Of Exchange Rate Changes | $1,888,000 | $-2,181,000 | $168,000 | $-272,000 |
| Changes In Cash | $-139,395,000 | $159,099,000 | $97,460,000 | $10,751,000 |
| Proceeds From Stock Option Exercised | $31,819,000 | $17,174,000 | $20,413,000 | $21,552,000 |
| Common Stock Payments | $0 | $-100,387,000 | $0 | $0 |
| Net Issuance Payments Of Debt | $-2,485,000 | $-2,276,000 | $-1,981,000 | $-1,751,000 |
| Net Long Term Debt Issuance | $-2,485,000 | $-2,276,000 | $-1,981,000 | $-1,751,000 |
| Long Term Debt Payments | $-2,485,000 | $-2,276,000 | $-1,981,000 | $-1,751,000 |
| Net Investment Purchase And Sale | $-340,861,000 | $97,706,000 | $625,000 | $74,088,000 |
| Sale Of Investment | $14,876,000 | $130,616,000 | $82,565,000 | $74,088,000 |
| Purchase Of Investment | $-355,737,000 | $-32,910,000 | $-81,940,000 | $0 |
| Net PPE Purchase And Sale | $-63,729,000 | $-21,182,000 | $-15,213,000 | $-19,298,000 |
| Purchase Of PPE | $-63,729,000 | $-21,182,000 | $-15,213,000 | $-19,298,000 |
| Change In Working Capital | $-42,716,000 | $-23,780,000 | $-79,084,000 | $-121,535,000 |
| Change In Payables And Accrued Expense | $15,977,000 | $18,229,000 | $7,318,000 | $23,927,000 |
| Change In Accrued Expense | $12,910,000 | $14,057,000 | $6,221,000 | $10,542,000 |
| Change In Payable | $3,067,000 | $4,172,000 | $1,097,000 | $13,385,000 |
| Change In Account Payable | $3,067,000 | $4,172,000 | $1,097,000 | $13,385,000 |
| Change In Prepaid Assets | $-12,697,000 | $-2,948,000 | $-18,909,000 | $-1,237,000 |
| Change In Inventory | $-26,482,000 | $-65,658,000 | $-67,710,000 | $-74,631,000 |
| Change In Receivables | $-19,514,000 | $26,597,000 | $-266,000 | $-69,857,000 |
| Changes In Account Receivables | $-19,514,000 | $26,597,000 | $-266,000 | $-69,857,000 |
| Other Non Cash Items | $205,000 | $4,121,000 | $20,553,000 | $1,274,000 |
| Stock Based Compensation | $59,213,000 | $46,164,000 | $50,516,000 | $37,378,000 |
| Asset Impairment Charge | $5,769,000 | $120,601,000 | $6,198,000 | $3,445,000 |
| Deferred Tax | $21,034,000 | $-16,339,000 | $-19,061,000 | $1,458,000 |
| Deferred Income Tax | $21,034,000 | $-16,339,000 | $-19,061,000 | $1,458,000 |
| Depreciation Amortization Depletion | $17,471,000 | $23,702,000 | $27,257,000 | $24,321,000 |
| Depreciation And Amortization | $17,471,000 | $23,702,000 | $27,257,000 | $24,321,000 |
| Net Income From Continuing Operations | $177,687,000 | $14,012,000 | $90,954,000 | $-2,002,000 |
| Income Tax Paid Supplemental Data | - | $20,674,000 | $6,557,000 | $2,919,000 |
| Net Business Purchase And Sale | - | - | $-988,000 | $0 |
| Sale Of Business | - | - | $0 | $0 |
| Purchase Of Business | - | - | $-988,000 | $0 |
| Change In Other Working Capital | - | - | $483,000 | $263,000 |
Fetched: 2026-06-21